Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced.

Breakpoint’s Managing Director Daniel Speidel will present a company overview during JPM at Biotech Showcase in San Francisco on January 9, 2024. Hilton Union Square 2:15 pm, Franciscan C.

Breakpoint’s Managing Director Jon Hollick will present a company overview at the LSX Inv€$tival Showcase in London on November 13, 2023.

Breakpoint’s Managing Director Daniel Speidel will present a company overview at BIO International Convention in Boston on June 7, 2023. 12:15pm, Session Room 104A.

Biotechnology Value Fund (BVF Partners), a San Francisco-based private investment partnership, has contributed capital in an extension of Breakpoint Therapeutics’ last funding round. Gorjan Hrustanovic, Managing Director at BVF Partners, will join Breakpoint’s Advisory Board as an Observer.